TYK2 Inhibitor for the Treatment of Plaque Psoriasis
The efficacy and safety of a once daily oral tyrosine kinase 2 (TYK2) inhibitor for the treatment of plaque psoriasis is assessed.
Plaque Psoriasis
Steroid-Free Vtama Cream Approved for Plaque Psoriasis
The approval was based on data from 2 identical phase 3 studies, PSOARING 1 and PSOARING 2.
FDA Decision on Bimekizumab for Plaque Psoriasis Delayed
Bimekizumab is an investigational humanized monoclonal IgG1 antibody that selectively inhibits both interleukin (IL)-17A and IL-17F.
Efficacy Response Maintained With Deucravacitinib in Plaque Psoriasis Trial
The POETYK PSO-LTE trial evaluated deucravacitinib 6mg orally once daily in 1221 adults with moderate to severe plaque psoriasis.
Patients With Psoriasis and Discrimination by Gut Microbiota
The composition and functional potential of gut microbiota in patients with psoriasis, including the role of seasonal instability, is examined.
Apremilast for Plaque Psoriasis of the Body and Scalp
A review regarding the safety, efficacy, and use of apremilast in treating patients with moderate to severe plaque psoriasis of the body and scalp, nail psoriasis, and palmoplantar psoriasis in adults is provided.
Mild Psoriasis Aligns With Patient-Reported Outcome of PASS
Mild psoriasis aligns well with the patient-reported outcome of patient acceptable symptom state (PASS).
Positive Psoriasis Response to Guselkumab, Regardless of MetS Status
The long-term efficacy and safety of guselkumab in patients with and without metabolic syndrome is assessed.
Improved Plaque Psoriasis Symptoms and Satisfaction With Brodalumab Therapy Reported
The effectiveness of brodalumab in improving psoriasis psoriasis treatment satisfaction in a population of Asian patients is evaluated.
Short-Term Air Pollution May Trigger Psoriasis Flares
Is short-term exposure to air pollutants associated with psoriasis flares?
- Loading...
Loading...
Next post in Psoriasis
Loading... 
Loading...